Reduction of [18F]FLT uptake in the tumor has also been used as imaging biomarker to predict overall survival of patients with GBM treated with bevacizumab [32], irinotecan [33] and an mTor inhibitor [34]. The gene discussed is MTOR; the disease is glioblastoma.